摘要
目的:观察溴夫定治疗带状疱疹的疗效。方法:采用平行对照的方法,将接受观察的106例患者按随机数字表法分成2组,每组各53例,其中治疗组采用溴夫定进行治疗,对照组采用阿昔洛韦进行治疗,疗程均为7 d,观察用药后第3、7、14、21、30 d分别对2组患者临床体征及症状上的改善情况。结果:治疗组和对照组对于治疗带状疱疹的有效率比较,差异无统计学意义;在镇痛时间、止疱时间及结痂时间上,治疗组明显短于对照组,差异有统计学意义(P<0.01);同时,带状疱疹后神经痛发生方面,治疗组明显少于对照组。结论:在对带状疱疹的治疗上,溴夫定的疗效和阿昔洛韦相当,但溴夫定对减轻带状疱疹后神经痛的效果明显。由此可见,溴夫定治疗带状疱疹安全、可靠。
OBJECTIVE：To investigate the efficacy and safety of brivudine for herpes zoster. METHODS： By parallel control method, a total of 106 patients with herpes zoster were randomly assigned to receive either brivudine （ treatment group, n = 53 ） or acyclovir （control group, n = 53 ） for 7 days. Follow-up of the improvements in clinical signs and symptoms of two groups were scheduled at 3, 7, 14, 21, 30 days, respectively. RESULTS ： With regard to response rate for herpes zoster, no statistical differences were noted between the two groups; however, statistical differences were noted between the two groups in time to analgesia, blister disappearance and incrustation, with significantly shorter time needed in the treatment group than in the control group （P 〈 0. 01 ） ; moreover, the treatment group was significantly superior to the control group in the incidence of postherpetic neuralgia incidence. CONCLUSION： In the treatment of herpes zoster, brivudine is as effective as acyclovir yet the former has better efficacy in lessening the incidence of postherpetic neuralgia, thus brivudine is safe and reliable for herpes zoster.
出处
《中国医院用药评价与分析》
2013年第3期255-256,共2页
Evaluation and Analysis of Drug-use in Hospitals of China
